Короткий опис (реферат):
The master's thesis analyzes modern scientific and practical sources and
reveals the relevance of optimizing antiallergic pathogenetic therapy and
prevention of seasonal allergic diseases of the respiratory tract. The problem of
pollinoses is becoming widespread in the southern regions of Ukraine and in the
country as a whole. A comparative analysis of the relevant allergic conditions in
Morocco confirmed the existing world statistics. The main clinical
manifestations are mainly allergic rhinitis and conjunctivitis, and this again
coincides in two countries (Ukraine and Morocco), the symptoms of which are
determined in patients when they apply to medical and preventive institutions or
directly to the pharmacy. In Ukraine at the border - the end of March - the
beginning of April, the end of May - the beginning of June, the end of August -
the beginning of September - the flowering period of trees - maple, birch, oak; -
cereal grasses - timothy, hedgehog, fescue, common fescue; - weed pollen -
wormwood, ragweed, wheatgrass, quinoa - the main clinical manifestations are
determined. In Morocco, the most dangerous time of year for hay fever is spring
and summer. Symptoms are primarily triggered by regional plants: Olive Trees,
Cypress Trees, Plane Trees, Grasses, Ragweed – Ambrosia, Parietaria, Acacia
Trees, Palm Trees. Together with windy weather, high air temperature, solar
activity, man-made pollutants contribute to the hypersensitivity of the
population and sensitization to plant pollen.
This requires appropriate attention, constant monitoring of the patient's
condition, the effectiveness and safety of mono- or combination therapy by both
doctors of various specialties, pharmacists, and the patients themselves. The
assessment of the clinical effectiveness of the drugs, together with the economic
analysis of the use of antihistamines, allows us to achieve the main goal -
prevention of symptoms, rapid recovery through the use of effective and safe
drugs, and rational use of private and public funds.
